$Coherus BioSciences (CHRS.US)$ Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 Wednesday, 22nd January at 7:00 am – Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor activity was observed across both viral and non-viral etiologies – – Data support continued...
Trytosaveabit
OP
Lnova
:
That I’m not positive of? I know it says D but the code F states that they were taken using money removed directly from his pay for tax liability So since they have good news coming possibly. I would leave each to make up their minds on it! Hehehe. Hope that makes sense? Hehehe
Note: The presence of 30 stock picks reflects the reality that not all stocks respond to their press releases immediately. For instance, today’s market activity saw certain high-performing stocks overshadow promising PRs, suggesting that it may take a day, several days, or even a week for the market to fully digest and react. I encourage you to save the watchlist I p...
Ducati999
:
Just wait. this ticker is full of shorters need to squeeze them a bit. they just actualize half a billion revenue and the market cap is 225mil. doesn’t sound logical right.
Coherus BioSciences Stock Forum
If you do not vote, its as good as voting against.
gov/Archives/ed...
Top Watch for Monday 1/27
$HOLO (1.56) Inv. Hammer Fri
$HEPA (.19c) Big move com...
📊⚡️📊
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Wednesday, 22nd January at 7:00 am
– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate –
– Antitumor activity was observed across both viral and non-viral etiologies –
– Data support continued...
No comment yet